CLOPIDOGREL BISSULFATE ACTION ON THROMBOELASTOMETRIC PROFILE ON ACTH-DEPENDENT HYPERADRENOCORTICISM DOGS THERAPY

• Grant number: 18/16767-2
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2019
• End date: February 28, 2021
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Regina Kiomi Takahira
• Grantee: Regina Kiomi Takahira
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• City of the host institution: Botucatu
• Associated researchers: Bruna dos Santos ; Felipe Gazza Romão ; Pedrita Carvalho Ferreira Assunção ; Viviani De Marco

Abstract

Several pathogenic conditions can lead to a state of hypercoagulability, which can lead to thrombi formation and/or disseminated intravascular coagulation. Nevertheless, classical hemostatic techniques, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), are not adequate to determine hypercoagulability. The more appropriate method for detection of either hypocoagulability or hypercoagulability is thromboelastometry. It is an in vitro test that integrates cell and soluble components of hemostatic process, in order to ensure a general assessment of hemostasis. The hyperadrenocorticism can lead to a hypercoagulability state supposedly due to increased activity of coagulation factors and fibrinogen concentration, in addition to decreased antithrombin activity, mainly by glomerulonephritis and proteinuria. The aim of this study is to evaluate the clopidogrel bisulfate capacity of attenuating the hypercoagulability state in dogs diagnosed with hyperadrenocorticism. For this purpose, a prospective and randomized clinical trial will be performed, in which patients will be characterized regarding their hemostatic profile on the admission date and after three months on therapy. With the obtained results, we attempt a better understanding of the frequency at which the hypercoagulability occurs on this disease, in the addition to the possible antithrombotic action of clopidogrel bisulfate and the effects of trilostane over hypercoagulability state. (AU)